In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aurinia Pharmaceuticals Inc.

www.auriniapharma.com

Latest From Aurinia Pharmaceuticals Inc.

Keeping Track: A Duo Of RTOR Approvals, Thumbs Up For First Oral GLP-1 Treatment, And First Ebola Vaccine Nears US Market

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Breakthrough Designation Confirms Gazyva Promise In Lupus Nephritis

Promising Phase II data mean it could be third time lucky for Roche in disease with no approved treatments. 

 

Commercial North America

Gazyva Succeeds In NOBILITY Lupus Nephritis Study But What Next?

Genentech refrained from committing to further development of its CD20 inhibitor in the indication despite meeting endpoints in Phase II study.

Renal Immune Disorders

Takeda Offloads Xiidra As Expected, For $3.4bn Upfront To Novartis

As widely anticipated, Takeda has reached an agreement to divest an ex-Shire ophthalmology drug, as it streamlines the combined post-acquisition business to focus on core therapeutic pillars.

Ophthalmic Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Renal System
  • Alias(es)
  • Isotechnika Pharma Inc.
  • Isotechnika Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Aurinia Pharmaceuticals Inc.
  • Senior Management
  • Peter Greanleaf, CEO
    Dennis Bourgeault, CFO
    Neil Solomons, MD, CMO
    Michael Martin, COO
  • Contact Info
  • Aurinia Pharmaceuticals Inc.
    Phone: (250) 708-4272
    1203-4464 Markham St.
    Victoria, V8Z 7X8
    Canada
UsernamePublicRestriction

Register